UTRECHT, The Netherlands, November 2 /PRNewswire/ -- InteRNA Technologies B.V. and the Dana-Farber Cancer Institute (Boston, USA) have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for cancer.
Under the research collaboration with Associate Professor William C. Hahn, MD, PhD (Department of Medical Oncology), InteRNA's unique lentiviral-based miRNA overexpression library will be applied in multi-parametric, high-throughput functional screening assays to identify the biological role of individual miRNAs and novel therapeutic targets in diverse cancer pathways.
We are very excited about this collaboration with Dr. Hahn, a renowned cancer investigator, and the Dana-Farber, as it allows for functional screens in diverse cell based assays embedded in a lab with extensive knowledge of cancer, said Roel Schaapveld, Chief Executive Officer of InteRNA Technologies.
These functional screens hold great promise to help us better understand the roles of miRNAs in cancer and to identify potential treatment targets, said Dr. Hahn of Dana-Farber Cancer Institute.
About InteRNA Technologies B.V.
InteRNA Technologies B.V. actively explores and exploits opportunities to translate its unique collection of miRNAs and miRNA discovery and validation technologies into successful diagnostic, prognostic and therapeutic applications. The company's primary focus is to unravel the role of its proprietary miRNAs in cancer.
InteRNA Technologies was incorporated in 2006 by Aglaia Oncology Fund and has established close relationships with the research groups of its founders Edwin Cuppen, PhD, and Eugene Berezikov, PhD, of the Hubrecht Institute (Utrecht, the Netherlands), leading scientific groups in the field of miRNA research.
See for more information http://www.interna-technologies.com.
SOURCE: InteRNA Technologies B.V.
CONTACT: Roel Schaapveld, PhD, MBA, CEO, InteRNA Technologies B.V. Phone: +31-(0)-302-532-386, E-mail: firstname.lastname@example.org